Problem

Olio Labs targets a central bottleneck in drug discovery: conventional therapeutics often focus on one or two proteins, even though those proteins operate across many organs and biological pathways. That narrow targeting can create off-target effects, while finding an effective multi-drug combination is prohibitively difficult because the number of possible combinations reaches into the trillions. The broader drug-development economics are severe: roughly 90% of drugs fail in clinical trials after more than a decade of work and approximately $2 billion in development costs.

Its clearest use case is obesity treatment, where GLP-1 drugs such as semaglutide and tirzepatide can produce substantial weight loss but are limited by nausea, vomiting, and discontinuation. Olio’s 2025 research found that women experience more than twice the rate of persistent nausea and vomiting on GLP-1 agonists, highlighting the opportunity to preserve efficacy while improving tolerability and tailoring treatment to biologically distinct patient groups.

Product / Service

Olio Labs is building an AI- and machine-learning-driven computational platform for combination therapeutics. It models the interactions of thousands of proteins and rapidly tests potential drug combinations in silico, narrowing the search to the most promising candidates before expensive cell, animal, and clinical work. The company says its approach has produced lead combinations that outperform market-leading obesity drugs; an investor description claims the compute-and-experiment workflow has accelerated discovery fourfold and reduced costs by 90%.

The platform is complemented by preclinical experimentation, including an instrumented home-cage system that continuously monitors animal behavior and physiology. The system generates roughly 2.5 million data points per mouse per day, captures richer data than a standard metabolic cage, and costs about one-fifth as much. Olio appears to operate as a biotech R&D platform and collaborative partner, offering computational combination-design support and clinical-trial consulting rather than selling a conventional standalone software product.

Market

Olio competes in AI-enabled drug discovery, computational biology, and biopharmaceutical therapeutics, with a specific focus on multi-agent or combination therapy design for complex diseases. Its closest competitive set is the broader group of AI drug-discovery companies, including Recursion and Insilico Medicine, although Olio’s differentiation is its emphasis on optimizing combinations and accounting for system-level protein interactions rather than primarily discovering single novel targets or molecules. The initial commercial and clinical opportunity appears to center on obesity and GLP-1 alternatives, with expansion planned across additional indications.

The company is an active Summer 2023 Y Combinator startup. Public traction includes published preclinical research on sex differences in GLP-1 response, a reported pipeline of lead combinations that beat currently available market-leading drugs, and a $4.5 million funding round announced in March 2025; a startup-tracking source reports $9 million raised across two rounds. Public sources reviewed do not disclose revenue, clinical-stage candidates, or named pharmaceutical customers, so Olio is best viewed as an early, preclinical and likely pre-revenue biotech platform, while its requests for pharmaceutical connections and molecule leads indicate that it is pursuing partnerships and external validation.